Okayama University Medical Research Updates （OU-MRU） Vol.35
February 27, 2017
Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 27 February 2017
Okayama University research: Potential cause of Lafora disease revealed
(Okayama, 27 February) Researchers at Okayama University report in the journal Matters, a potential third factor in the pathogenesis of Lafora disease. In addition to gene mutations, chemical modification of the enzyme Laforin induced by nitrosative stress is found to be a likely cause of the illness too.
Lafora disease is a fatal illness characterized by the abnormal generation of glycogens within neurons and other cells, for which no cure exists. Classified as a neurodegenerative disorder, it is caused by gene mutations that affect the production of two enzymes in the human body, Laforin and Malin. A team of researchers from Okayama University led by Ayano Satoh have now identified another potential cause of Lafora disease: when Laforin undergoes a particular reaction known as S-nitrosylation, the enzyme stops functioning properly.
The researchers reasoned that since S-nitrosylation has been linked to the development of other neurodegenerative diseases like Alzheimer’s and Parkinson’s, the reaction may also play a role in the pathogenesis of Laforin disease. They first confirmed that S-nitrosylation does take place by letting Laforin react with nitric oxide (NO). The authors then investigated whether the S-nitrosylation of Laforin affected its three biochemical functions.
One of Laforin’s roles is to remove the phosphates that get incorporated, due to enzymatic errors, in glycogens. This is a three-step process: Laforin binds to the glycogen, removes the phosphate, and then binds to Malin. Satoh and colleagues checked whether S-nitrosylated Laforin still binds to glycogens and to Malin; their results suggest that modified Laforin has the same binding capacities as unmodified Laforin. Laforin’s ability to remove phosphate groups — its phosphatase function — was, however, found to be inhibited after
S-nitrosylation. The authors then looked at what happened when treating cells expressing non-mutated Laforin with an NO donor. A comparison with untreated cells revealed that 40% more Lafora bodies were formed when Laforin was treated with NO; Lafora bodies are the inclusion bodies characteristic of Lafora disease, consisting of accumulated glycogen with excessive phosphate content and precipitating inside cells.
The findings of Satoh and colleagues show that the decreased phosphatase activity of Laforin triggered by an overproduction of NO — as the result of a disrupted redox balance in cells— may be a cause, other than gene mutation, of Lafora disease. In the words of the researchers: “Lafora disease phenotypes can be caused by nitrosative stress”. Additional research is needed for precisely determining Laforin’s S-nitrosylation sites, and a further next step will be repeating the experiments in animal cells or neurons.
Lafora disease is a neurodegenerative disorder, like Alzheimer’s, Parkinson’s and Huntington’s. In the case of Lafora disease, disordered cell metabolism leads to the accumulation of insoluble particles (called Lafora bodies) within the cytoplasm of cells in various parts of the human body. Symptoms appear in the patient’s teenage years. Lafora disease is fatal; patients usually die within ten years after the first symptoms.
Known causes of the generation of Lafora bodies are mutations of genes that encode two enzymes, Laforin and Malin. The latter is a so-called E3 ubiquitin ligase: a protein that assists in transferring a ubiquitin molecule (a very common regulatory protein) from an E2 enzyme (an enzyme capable of carrying ubiquitin) to a substrate peptide. Laforin is a so-called glucan phosphatase: its function is to liberate phosphate groups from glucans (clusters consisting of a large number of glucose molecules). In the context of Lafora disease, the relevant glucans are glycogens (multi-branched strands of glucose molecules organized into a globular structure); Lafora bodies largely consist of phospho-glycogens. The presence of phosphates in glycogen makes it insoluble — hence the precipitation of Lafora bodies.
Satoh and colleagues hypothesized that not only mutations can cause Lafora disease, but also a certain type of chemical reaction involving Laforin: S-nitrosylation. This reaction modifies Laforin to such an extent that it can no longer perform its phosphate-liberating function. The researchers showed that Laforin molecules can indeed undergo S-nitrosylation reactions and that they lead to the increased formation of Lafora bodies in cells expressed with Laforin.
By producing specific amounts of reactive oxygen species (ROS), reactive nitrogen species (RNS) and an antioxidant system, cells are able to maintain the redox-state balance necessary for proper metabolic functioning. In case of overproduction of ROS and RNS (‘nitrosative stress’), reactions can be triggered that cause a disruption of cell metabolism. Nitric oxide (NO) is a ROS/RNS compound, and can react with Laforin; the reaction is known as S-nitrosylation. Because S-nitrosylation is recognized as a pathogenesis for Alzheimer’s and Parkinson’s diseases, the researchers proposed that it also plays a role in Laforin disease. They found that S-nitrosylated Laforin loses its phosphatase function, and that nitrosative stress may therefore be another cause of Lafora disease.
Rikako Toyota, Yasuko Honjo, Risa Imajo, Ayano Satoh. S-nitrosylation of laforin inhibits its phosphatase activity and is implicated in Lafora disease. Matters, Sep 8th, 2016.
Associate Professor Ayano Satoh, Ph.D.
Organelle Systems Biotechnology,
Department of Medical Bioengineering, Graduate School of Natural
Science and Technology, Okayama University,
3-1-1 Tsushimanaka, Kita-ku, Okayama 700-8530, Japan
e-mail : ayano113(a) cc.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
Okayama Univ. e-Bulletin (PDF Issues): //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube): https://www.youtube.com/watch?v=_WnbJVk2elA
Okayama University Medical Research Updates （OU-MRU）
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealedVol.31：Prevention of RNA virus replicationVol.32：Enzyme target for slowing bladder cancer invasionVol.33：Attacking tumors from the insideVol.34：Novel mouse model for studying pancreatic cancer